Mays Charles E, van der Merwe Jacques, Kim Chae, Haldiman Tracy, McKenzie Debbie, Safar Jiri G, Westaway David
Centre for Prions and Protein Folding Diseases, University of Alberta, Edmonton, Alberta, Canada.
National Prion Disease Pathology Surveillance Center, Case Western Reserve University, Cleveland, Ohio, USA.
J Virol. 2015 Dec;89(24):12418-26. doi: 10.1128/JVI.02142-15. Epub 2015 Sep 30.
In lethal prion neurodegenerative diseases, misfolded prion proteins (PrP(Sc)) replicate by redirecting the folding of the cellular prion glycoprotein (PrP(C)). Infections of different durations can have a subclinical phase with constant levels of infectious particles, but the mechanisms underlying this plateau and a subsequent exit to overt clinical disease are unknown. Using tandem biophysical techniques, we show that attenuated accumulation of infectious particles in presymptomatic disease is preceded by a progressive fall in PrP(C) level, which constricts replication rate and thereby causes the plateau effect. Furthermore, disease symptoms occurred at the threshold associated with increasing levels of small, relatively less protease-resistant oligomeric prion particles (oPrP(Sc)). Although a hypothetical lethal isoform of PrP cannot be excluded, our data argue that diminishing residual PrP(C) levels and continuously increasing levels of oPrP(Sc) are crucial determinants in the transition from presymptomatic to symptomatic prion disease.
Prions are infectious agents that cause lethal brain diseases; they arise from misfolding of a cell surface protein, PrP(C) to a form called PrP(Sc). Prion infections can have long latencies even though there is no protective immune response. Accumulation of infectious prion particles has been suggested to always reach the same plateau in the brain during latent periods, with clinical disease only occurring when hypothetical toxic forms (called PrP(L) or TPrP) begin to accumulate. We show here that infectivity plateaus arise because PrP(C) precursor levels become downregulated and that the duration of latent periods can be accounted for by the level of residual PrP(C), which transduces a toxic effect, along with the amount of oligomeric forms of PrP(Sc).
在致死性朊病毒神经退行性疾病中,错误折叠的朊病毒蛋白(PrP(Sc))通过改变细胞朊病毒糖蛋白(PrP(C))的折叠来进行复制。不同持续时间的感染可能有一个亚临床阶段,其中感染性颗粒水平保持恒定,但这种平台期以及随后进入明显临床疾病的潜在机制尚不清楚。通过串联生物物理技术,我们发现,在症状前疾病中,感染性颗粒的积累减弱之前,PrP(C)水平会逐渐下降,这会限制复制速率,从而导致平台效应。此外,疾病症状出现在与较小的、相对蛋白酶抗性较低的寡聚朊病毒颗粒(oPrP(Sc))水平增加相关的阈值处。虽然不能排除存在一种假设的致死性PrP异构体,但我们的数据表明,残余PrP(C)水平的降低和oPrP(Sc)水平的持续增加是从症状前朊病毒疾病转变为症状性疾病的关键决定因素。
朊病毒是导致致命性脑部疾病的感染因子;它们由细胞表面蛋白PrP(C)错误折叠为一种称为PrP(Sc)的形式而产生。即使没有保护性免疫反应,朊病毒感染也可能有很长的潜伏期。有人提出,在潜伏期,感染性朊病毒颗粒的积累在大脑中总是会达到相同的平台期,只有当假设的毒性形式(称为PrP(L)或TPrP)开始积累时才会出现临床疾病。我们在此表明,感染性平台期的出现是因为PrP(C)前体水平下调,潜伏期的持续时间可以由残余PrP(C)的水平来解释,残余PrP(C)会产生毒性作用,同时还有PrP(Sc)寡聚形式的量。